# EDGAR Filing Document

**Accession Number:** 0001833141
**File Stem:** 0001628280-23-006927
**Filing Date:** 2023-3
**Character Count:** 5187
**Document Hash:** 338515cc736df004a146376a8ca7aad4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-006927.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001628280-23-006927

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230308

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYBIN INC.
- **CENTRAL INDEX KEY:** 0001833141
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40673
- **FILM NUMBER:** 23715454

**BUSINESS ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9
- **BUSINESS PHONE:** (908) 764-8385

**MAIL ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**<br>

For the month of March, 2023.

Commission File Number: **001-40673**

****<br>**<u>Cybin Inc.</u>**<br>(Exact Name of Registrant as Specified in Charter)<br>**100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9** 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

**Note**: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

**Note**: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br>

---

| | | | |
|:---|:---|:---|:---|
| | | **CYBIN INC.** | **CYBIN INC.** |
| | | (Registrant) | (Registrant) |
| Date: | March 8, 2023 | By: | */s/ Doug Drysdale&nbsp;&nbsp;&nbsp;&nbsp;*  |
|  |  | Name: | Doug Drysdale |
|  |  | Title: | Chief Executive Officer |

---

------

**<u>EXHIBIT INDEX</u>**

99.1 <u>[News Release dated March 8, 2023](cybnopcocurtainraiserpr3-8.htm)</u>

## Exhibit 99.1

![image_0a.jpg](image_0a.jpg)

**Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference**

<br>**TORONTO, CANADA** – March 8, 2023 – <u>Cybin Inc.</u> (NEO:CYBN) (NYSE American:CYBN) ("**Cybin**" or the "**Company**"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics<sup>®</sup> is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference taking place on March 13-15, 2023.

Mr. Drysdale's fireside chat will be webcast live on Tuesday, March 14, 2023 at 12:40 p.m. ET. To listen to the event, please <u>click here</u> to access the webcast. The archived webcast will also be available on the Company's investor relations website on the <u>Events & Presentations</u> page.

**About Cybin**

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

**Investor & Media Contact:** 

Leah Gibson

Vice President, Investor Relations & Strategic Communications

Cybin Inc.

<u>irteam@cybin.com</u> – or – <u>media@cybin.com</u> 

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

<br>